Dongcheng Pharmaceutical: The application for of Bemiparin Sodium has been accepted by the National Medical Products Administration.

Dongcheng Pharmaceutical announced that the company recently received an Acceptance Notice from the National Medical Products Administration regarding the listing application for the active pharmaceutical ingredient Bemiparin Sodium, with acceptance number CYHS2660516. Bemiparin Sodium is an ultra-low molecular weight heparin that has been marketed in over 60 countries worldwide and is suitable for preventing clotting in patients undergoing dialysis and for treating thromboembolic diseases in surgical patients. Subsequent work may still be affected by uncertainties, and the company will actively promote the next steps in the process.